Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
1.030
-0.060 (-5.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Lisata Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
These stocks are moving in today's after hours session
↗
July 28, 2026
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
July 21, 2026
Via
Chartmill
The market is filled with gapping stocks in Tuesday's session.
↗
July 21, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
July 21, 2026
Via
Chartmill
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Earnings Outlook For Lisata Therapeutics
↗
November 11, 2024
Via
Benzinga
Recap: Lisata Therapeutics Q4 Earnings
↗
February 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
July 09, 2026
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics...
Via
Benzinga
In today's session, these stocks are experiencing unusual volume.
↗
January 27, 2026
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
January 22, 2026
Via
Chartmill
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details
↗
January 21, 2026
Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.
Via
Stocktwits
Topics
Workforce
Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss
↗
November 06, 2025
Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027.
Via
Chartmill
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Lisata Therapeutics's Earnings Outlook
↗
February 28, 2024
Via
Benzinga
Earnings Preview: Lisata Therapeutics
↗
November 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 04, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
July 21, 2025
Via
Benzinga
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
↗
January 22, 2025
Via
Benzinga
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings
↗
January 22, 2025
Via
Benzinga
US Stocks Higher; Netflix Profit Beats Estimates
↗
January 22, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
January 22, 2025
Via
Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
January 22, 2025
Via
Benzinga
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
↗
August 12, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
↗
July 18, 2024
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing...
Via
Benzinga
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
May 13, 2024
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via
News Direct
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024
↗
May 09, 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
